Loading...
Receive $200 for creating an Interactive Brokers account using our link: Create IBKR account. Read our Interactive Brokers analysis
- Ticker
- CTXR
- Price
- 0.74
- Stock movement down
- -0.02 (-3.10%)
- Company name
- Citius Pharmaceuticals Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 16.59M
- Ent value
- 55.79M
- Price/Sales
- 4.21
- Price/Book
- 0.18
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- 0.27
- PEG
- -
- EPS growth
- -20.02%
- 1 year return (CAGR)
- -72.54%
- 3 year return (CAGR)
- -72.46%
- 5 year return (CAGR)
- -53.81%
- 10 year return (CAGR)
- -
Last updated: 2026-03-13
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
CTXR does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 4.21 |
| Price to Book | 0.18 |
| EV to Sales | 14.15 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 22.38M |
| EPS (TTM) | -1.67 |
| FCF per share (TTM) | -1.62 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 3.94M |
| Gross profit (TTM) | 2.42M |
| Operating income (TTM) | -37.51M |
| Net income (TTM) | -35.89M |
| EPS (TTM) | -1.67 |
| EPS (1y forward) | 2.79 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 61.41% |
| Operating margin (TTM) | -950.92% |
| Profit margin (TTM) | -909.87% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 7.72M |
| Net receivables | 4.05M |
| Total current assets | 37.95M |
| Goodwill | 9.35M |
| Intangible assets | 92.23M |
| Property, plant and equipment | 835.18K |
| Total assets | 140.39M |
| Accounts payable | 11.02M |
| Short/Current long term debt | 829.65K |
| Total current liabilities | 38.21M |
| Total liabilities | 46.92M |
| Shareholder's equity | 93.47M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -34.84M |
| Capital expenditures (TTM) | 8.00 |
| Free cash flow (TTM) | -34.84M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -38.39% |
| Return on Assets | -25.56% |
| Return on Invested Capital | -38.33% |
| Cash Return on Invested Capital | -37.21% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 0.77 |
| Daily high | 0.77 |
| Daily low | 0.68 |
| Daily Volume | 535K |
| All-time high | 937.54 |
| 1y analyst estimate | 6.00 |
| Beta | 1.56 |
| EPS (TTM) | -1.67 |
| Dividend per share | 0.00 |
| Ex-div date | - |
| Next earnings date | - |
Downside potential
Loading...
Downside potential data
| CTXR | S&P500 | |
| Current price drop from All-time high | -99.92% | -1.82% |
| Highest price drop | -99.93% | -56.47% |
| Date of highest drop | 30 May 2025 | 9 Mar 2009 |
| Avg drop from high | -91.94% | -10.84% |
| Avg time to new high | 209 days | 12 days |
| Max time to new high | 2450 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
16.59M
Marketcap category
Small-cap
Description
Citius Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of critical care products. Its LYMPHIR, an FDA-approved product, is a targeted immunotherapy for the treatment of cutaneous T-cell lymphoma. The company's late-stage pipeline includes Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections; Halo-Lido, a corticosteroid-lidocaine topical formulation to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; and NoveCite, a mesenchymal stem cell therapy for the treatment of ARDS. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.
Employees
23
Website
Investor relations
-
SEC filings
CEO
Myron Z. Holubiak
Country
USA
City
Cranford
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page